Based on their results, they propose utilization of IDH inhibitor and ICB in the clinical practices to treat IDH‐mutant glioma [79], which indeed would be particularly valuable for the PMMRDIA group, which is otherwise resistant to TMZ. Here, IDH1 is linked to central nervous system cancer.